L-Carnitine: Energy and Training

Current record

Added to the active ledger on September 10, 2026. The recorded schedule is 1,000 mg every other day post-workout, also listed in the Daily Stack. This replaces the earlier oral L-tartrate fat-loss proposal. The current question puts energy and training output first.

The hypothesis

Carnitine helps move long-chain fatty acids into mitochondria. My hypothesis is that improving that delivery could help sustain energy while the surrounding compounds increase expenditure. The assumption being tested is whether carnitine availability is actually limiting anything in this routine. More available carnitine does not by itself establish more muscle uptake, more fuel oxidation, or more usable ATP.

What would count as useful

The main observations are daily energy, the ability to sustain comparable training output, late-session fatigue, and recovery into the next session. Lifting comparisons will use the same movement and similar effort; cardio comparisons will use similar pace or workload with heart rate and perceived exertion recorded alongside. Matching positions in the nine-day training rotation matters more than comparing two different workouts on adjacent days.

Because the recorded timing is post-workout, the session that just ended cannot be evidence of an immediate response to that day's administration. Recovery, later-day energy, and subsequent sessions are the relevant comparisons. Exposure dates will be recorded separately from workout dates.

The surrounding record

Sleep, calorie and carbohydrate intake, the ongoing reverse diet, body-weight trend, and changes in ATX-304, SANA, BAM15, Cardarine, and CL belong on the same timeline. Weight, waist, and visual body composition remain secondary outcomes. A repeatable improvement in energy or training would be useful on its own. The experiment is active; no new outcome is recorded yet.

Blood availability and muscle uptake are different steps

In an acute randomized crossover study, intravenous carnitine raised circulating availability without increasing muscle total carnitine or changing fuel metabolism during exercise. A separate study in eight men found that muscle carnitine increased during an infusion when insulin was held high, but not when insulin remained at fasting levels. Together, those studies make tissue uptake central to the question. They do not establish that more circulating carnitine automatically reaches the working muscle. Brass et al., 1994; Stephens et al., 2006.

The strongest direct muscle-loading example

A randomized study of 14 men used oral L-carnitine L-tartrate with substantial carbohydrate intake twice daily for 24 weeks. Muscle carnitine increased by 21% in the carnitine group, with altered fuel use and an 11% improvement in work output from baseline; the control group showed no performance change. The significant effects appeared at 24 weeks. This establishes that muscle loading and a performance effect are possible under those conditions. It does not establish the same response from the current every-other-day schedule. Wall et al., 2011.

A fatigue signal during restricted intake

A seven-day pilot trial in 30 people with metabolic syndrome found less reported fatigue and hunger with intravenous L-carnitine during modified fasting. It used 4 g/day and studied a very different setting from normal training during a cut. The useful connection is the energy question, not a match to this exposure or evidence for this compound combination. Zhang et al., 2014.

Why ATX-304, SANA, and BAM15 matter here

BAM15 increases mitochondrial proton leak. ATX-304 has AMPK-related activity and reported mitochondrial proton-leak effects. SANA promotes creatine-dependent thermogenesis in adipose tissue; it does not directly uncouple isolated mitochondria. These mechanisms can raise metabolic demand through different routes. The idea that carnitine supports my energy in that setting is a personal combination hypothesis. Greater fuel oxidation alone would not show that more ATP was available for training.

Tolerability is part of the result

The supplement literature describes gastrointestinal symptoms and fishy body odor, with additional concerns in kidney disease and seizure disorders. Oral and intravenous studies provide different exposure evidence, so their results should retain their route and context. Any new symptoms belong beside the energy and training observations. NIH Office of Dietary Supplements.

Sources

• Brass et al., Clinical Pharmacology & Therapeutics, 1994 — acute intravenous carnitine, muscle content, and exercise fuel metabolism.
• Stephens et al., FASEB Journal, 2006 — insulin-dependent muscle uptake during carnitine infusion.
• Wall et al., Journal of Physiology, 2011 — muscle loading, fuel use, and performance after 24 weeks.
• Zhang et al., Nutrition Journal, 2014 — pilot trial of fatigue and hunger during modified fasting.
• Kenwood et al., Molecular Metabolism, 2014 — identification of BAM15 as a mitochondrial uncoupler.
• Norlin et al., Communications Biology, 2023 — O304/ATX-304 mitochondrial and metabolic activity.
• Cal et al., Nature Metabolism, 2025 — SANA and creatine-dependent thermogenesis.
• NIH Office of Dietary Supplements: Carnitine — physiology and clinical safety context.